Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piceatannol is a naturally occurring polyphenolic stilbenoid and phenol found in various fruits and vegetables such as grapes and passion fruit. It is also a metabolite of resveratrol formed via cytochrome P450-mediated hydroxylation[7][1]. Piceatannol acts as a protein kinase inhibitor—most notably inhibiting the tyrosine kinase Syk—and has demonstrated antineoplastic (anticancer), anti-inflammatory, antiangiogenic (inhibiting VEGF-mediated signaling), hypoglycemic (blood sugar-lowering), and geroprotective properties[1][6][5]. Mechanistically it inhibits Syk-dependent signaling pathways in immune cells and blocks VEGF-induced angiogenesis by interfering with VEGF binding to its receptors[6][5]. It also activates SIRT1 deacetylase activity[5]. While preclinical studies suggest potential for treating metabolic diseases (such as obesity-related disorders), cancer, cardiovascular disease (including atherosclerosis), and angiogenesis-related conditions, clinical development remains limited to experimental or early-stage research[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piceatannol.